Phreesia competitors

Mark T. Bertolini (born 1956) is an American businessman who was the CEO of Aetna, a Fortune 50 diversified health care benefits company with over $60 billion in 2015 revenue. Bertolini assumed the role of CEO on November 29, 2010 and of Chairman on April 8, 2011 until Aetna was sold to CVS on November 28, 2018.

Passionate and relentless CEO and Board Member in the Software & IT Services industry with over 20 years of broad-based functional experience in sales, marketing, corporate strategy, M&A, business process outsourcing and P&L management. Extensive experience in managing global organizations with significant operations in North America, Europe, Asia Pacific, Japan and Brazil.Often called upon to solve complex and difficult problems that require both strategic insight and focused operational discipline to resolve. Recent PE-backed assignments have taught me valuable lessons in building and aligning teams, negotiating strategic exits, working collaboratively with a Board, and dealing with the challenges of highly leveraged financial models.Bottom-line, I enjoy building teams and inspiring them to achieve what they did not think was possible!

Jim Love joined Wellpartner as President in December 2011 and was named Chief Executive Officer in April 2012. Prior to joining Wellpartner, Mr. Love had significant healthcare experience in both operations and investment banking. He spent the early part of his career in the investment banking division of Merrill Lynch & Company where he led the healthcare group and provided both strategic and financing advice to a wide range of companies including Johnson & Johnson, Hospital Corporation of America, Medco, and Biogen Idec. Mr. Love left Merrill Lynch to serve as Executive Vice President of Synetic Inc. (and its successor company Medical Manager, Inc.) a publicaly traded healthcare information technology company, where he was responsible for all finance and administrative functions. During his tenure at Synetic, Mr. Love led the efforts to raise both debt and equity capital, acquire several business, and ultimately merge the company with WebMD. After the merger with WebMD, Mr. Love returned to the investment banking business, at the Bank of Montreal, where he rebuilt the firm’s commercial and investment banking healthcare effort, and at Madison Williams and Company, where he was a senior investment banker. Mr. Love received an A.B. degree from Brown University, and a M.B.A degree from New York University.

Kurt Graves is the Chairman, President and Chief Executive Officer of Intarcia. Prior to joining Intarcia, Mr. Graves was EVP, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals. Prior to his tenure at Vertex, he spent nearly 10 years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Mr. Graves also previously held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals, where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. Mr. Graves earned his B.S. in biology from Hillsdale College and has attended executive leadership programs at Harvard University, the University of Pennsylvania Wharton School of Management and University of Michigan.

Jason Kelly co-founded Ginkgo BioWorks in 2008. The organism is the product at Ginkgo BioWorks. Ginkgo's organism engineers design microbes made-to-order for customers across a range of industries by leveraging a technology platform including custom hardware, software, and wetware. Jason earned his PhD from MIT in Biological Engineering in 2008, under professor Drew Endy, and his BS in Chemical Engineering and Biology in 2003. His doctoral research included the development of a widely adopted measurement standard for characterizing transcriptional elements.